NSE · Healthcare · Biotechnology
EPS came in at 3.33 against a street estimate of 3.52 — a miss of 5.4%.
with an average price target of ₹760.00.
CONFIDENT Q2 revenue grew 25% and H1 26%, led by APIs and newer products. Margins held despite input-cost pressure, while injectables, Stellon, dermatology and CDMO remain investments with execution risk. Q2 FY27 Domestic API growth was strongest. Reported exports may understate underlying demand because some customers procure through Indian subsidiaries before re-exporting. Analysts focused on API growth durability, weak formulation revenue, utilization, margin recovery, dermatology potential, CapEx and injectables contracts. Management emphasized new products, customer additions and future ramp-up, but several timelines remained qualitative. 2026-10-28…
Full summary in the app.
| Holder | Stake |
|---|---|
| Aryavir Jhunjhunwala Discretionary Trust | 8.03% |
| Aryaman Jhunjhunwala Discretionary Trust | 8.03% |
| Nishtha Jhunjhunwala Discretionary Trust | 8.03% |
| DSP Small Cap Fund | 3.21% |
| Government Pension Fund Global | 2.95% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call CONCORD BIOTECH LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Q1 FY27 Total Revenue: INR 257 crores – 26.2% year-on-year growth (vs INR | 2026-08-07 |
| Annual report FY2026 CONCORD BIOTECH LIMITED – ANNUAL REPORT FY2025-26 SUMMARY --- HEADLINE NUMBERS • Revenue from operations FY26: ₹1,054.9 crore (compared to ₹1,200.1 | 2026-07-07 |
| Q4 FY26 earnings call CONCORD BIOTECH LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue (FY26): INR 1,049 crores, down 12% year-on-year • Q4 FY26 Revenue: Down 2 | 2026-06-05 |
| Investor presentation · Q4 FY26 CONCORD BIOTECH LIMITED – INVESTOR SUMMARY Financial Year Ended March 31, 2026 --- HEADLINE NUMBERS • FY26 Revenue: Rs 1,054.9 Crores (down 12% YoY | 2026-05-30 |
| Quarterly results · Q4 FY26 CONCORD BIOTECH LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year Revenue from Operations (FY 2025-26): Rs. 1,05,507.10 lakhs (vs. Rs. 1,20,00 | 2026-05-30 |
| Q3 FY26 earnings call CONCORD BIOTECH LIMITED - Q3 & 9 MONTHS FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 278 crores (14% YoY growth vs INR 244 crores in Q3 FY25 | 2026-02-18 |
| Quarterly results · Q3 FY26 CONCORD BIOTECH LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Board meeting held on February 11, 2026 to approve Q3 FY2025-26 (quarter ended Decembe | 2026-02-11 |
| Investor presentation CONCORD BIOTECH LIMITED – INVESTOR SUMMARY Q3 & 9 MONTHS FY26 (ENDED DECEMBER 31, 2025) --- HEADLINE NUMBERS • Q3FY26 Revenue: Rs 277.8 crores (up | 2026-02-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Bonus issue | 1 : 1 ex-date Nov 4, 2026 | 2026-11-04 |
| Dividend | ₹7.55 / share ex-date Jul 24, 2026 | 2026-07-24 |
| Announcement | Date |
|---|---|
| Acquisition of another business entity announced Concord Biotech Limited has informed the Exchange about Acquisition | 2026-06-20 |
| Acquisition announced by the company Concord Biotech Limited has informed the Exchange about Acquisition | 2026-04-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Concord Biotech Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.